Xtant Medical to Issue Third Quarter 2023 Financial Results on November 9, 2023
Xtant Medical Holdings, Inc. will release its financial results for Q3 2023 on November 9, 2023. The company is a global medical technology company focused on surgical solutions for spinal disorders. President and CEO Sean Browne, and CFO Scott Neils, will host a conference call at 9:00 AM ET on the same day to review the results. The conference call details are provided in the press release.
11/02/2023 - 04:05 PM
BELGRADE, Mont., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, before the open of the financial markets on Thursday, November 9, 2023.
Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Thursday, November 9 at 9:00 AM ET to review results.
Conference Call Details: Conference Call Date: Thursday, November 9, 2023 - 9:00 AM ETConference Call dial-in: 877-407-6184International dial-in: 201-389-0877Conference Call Name: Xtant Medical Q3 2023 Financial ResultsWebcast Registration: Click Here
Following the live call, a replay will be available on the Company’s website, www.xtantmedical.com , under “Investor Info.”
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. (www.xtantmedical.com ) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Investor Relations Contact
David Carey Lazar FINN Partners Ph: 212-867-1762 Email: david.carey@finnpartners.com
When will Xtant Medical Holdings release its financial results for Q3 2023?
Xtant Medical Holdings will release its financial results for Q3 2023 on November 9, 2023.
What is Xtant Medical Holdings' focus?
Xtant Medical Holdings is a global medical technology company focused on surgical solutions for the treatment of spinal disorders.
Who will host the conference call to review Xtant Medical Holdings' financial results?
President and CEO Sean Browne, and CFO Scott Neils, will host the conference call to review Xtant Medical Holdings' financial results.
What is the date and time of the conference call?
The conference call will take place on Thursday, November 9, 2023, at 9:00 AM ET.
How can I access the conference call?
You can access the conference call by dialing 877-407-6184 (for US participants) or 201-389-0877 (for international participants).
Will there be a webcast of the conference call?
Yes, you can register for the webcast on Xtant Medical Holdings' website.
Where can I find a replay of the conference call?
A replay of the conference call will be available on Xtant Medical Holdings' website under 'Investor Info'.
Xtant Medical Holdings Inc
XTNT Rankings
#224 Ranked by Stock Gains
XTNT Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Belgrade
About XTNT
xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.